373 related articles for article (PubMed ID: 23838352)
1. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.
Tefferi A; Cervantes F; Mesa R; Passamonti F; Verstovsek S; Vannucchi AM; Gotlib J; Dupriez B; Pardanani A; Harrison C; Hoffman R; Gisslinger H; Kröger N; Thiele J; Barbui T; Barosi G
Blood; 2013 Aug; 122(8):1395-8. PubMed ID: 23838352
[TBL] [Abstract][Full Text] [Related]
2. Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis.
Bartoszko J; Panzarella T; Lau A; Schimmer A; Schuh A; Shanavas M; Yee K; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e151-6. PubMed ID: 26566925
[TBL] [Abstract][Full Text] [Related]
3. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Tefferi A; Barosi G; Mesa RA; Cervantes F; Deeg HJ; Reilly JT; Verstovsek S; Dupriez B; Silver RT; Odenike O; Cortes J; Wadleigh M; Solberg LA; Camoriano JK; Gisslinger H; Noel P; Thiele J; Vardiman JW; Hoffman R; Cross NC; Gilliland DG; Kantarjian H;
Blood; 2006 Sep; 108(5):1497-503. PubMed ID: 16675707
[TBL] [Abstract][Full Text] [Related]
4. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.
Barosi G; Mesa R; Finazzi G; Harrison C; Kiladjian JJ; Lengfelder E; McMullin MF; Passamonti F; Vannucchi AM; Besses C; Gisslinger H; Samuelsson J; Verstovsek S; Hoffman R; Pardanani A; Cervantes F; Tefferi A; Barbui T
Blood; 2013 Jun; 121(23):4778-81. PubMed ID: 23591792
[TBL] [Abstract][Full Text] [Related]
5. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).
Barosi G; Tefferi A; Besses C; Birgegard G; Cervantes F; Finazzi G; Gisslinger H; Griesshammer M; Harrison C; Hehlmann R; Hermouet S; Kiladjian JJ; Kröger N; Mesa R; Mc Mullin MF; Pardanani A; Passamonti F; Samuelsson J; Vannucchi AM; Reiter A; Silver RT; Verstovsek S; Tognoni G; Barbui T
Leukemia; 2015 Jan; 29(1):20-6. PubMed ID: 25151955
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
7. Speaking a common language in MDS/MPNs.
Steensma DP
Blood; 2015 Mar; 125(12):1849-51. PubMed ID: 25792730
[TBL] [Abstract][Full Text] [Related]
8. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Mesa RA; Verstovsek S; Cervantes F; Barosi G; Reilly JT; Dupriez B; Levine R; Le Bousse-Kerdiles MC; Wadleigh M; Campbell PJ; Silver RT; Vannucchi AM; Deeg HJ; Gisslinger H; Thomas D; Odenike O; Solberg LA; Gotlib J; Hexner E; Nimer SD; Kantarjian H; Orazi A; Vardiman JW; Thiele J; Tefferi A;
Leuk Res; 2007 Jun; 31(6):737-40. PubMed ID: 17210175
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
10. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Silver RT; Barel AC; Lascu E; Ritchie EK; Roboz GJ; Christos PJ; Orazi A; Hassane DC; Tam W; Cross NCP
Cancer; 2017 Jul; 123(14):2680-2687. PubMed ID: 28518222
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
Mascarenhas J; Migliaccio AR; Kosiorek H; Bhave R; Palmer J; Kuykendall A; Mesa R; Rampal RK; Gerds AT; Yacoub A; Pettit K; Talpaz M; Komrokji R; Kremyanskaya M; Gonzalez A; Fabris F; Johnson K; Dougherty M; McGovern E; Arango Ossa J; Domenico D; Farnoud N; Weinberg RS; Kong A; Najfeld V; Vannucchi AM; Arciprete F; Zingariello M; Falchi M; Salama ME; Mead-Harvey C; Dueck A; Varricchio L; Hoffman R
Clin Cancer Res; 2023 Sep; 29(18):3622-3632. PubMed ID: 37439808
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
[TBL] [Abstract][Full Text] [Related]
13. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.
Gotlib J; Pardanani A; Akin C; Reiter A; George T; Hermine O; Kluin-Nelemans H; Hartmann K; Sperr WR; Brockow K; Schwartz LB; Orfao A; Deangelo DJ; Arock M; Sotlar K; Horny HP; Metcalfe DD; Escribano L; Verstovsek S; Tefferi A; Valent P
Blood; 2013 Mar; 121(13):2393-401. PubMed ID: 23325841
[TBL] [Abstract][Full Text] [Related]
14. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.
Pemmaraju N; Carter BZ; Bose P; Jain N; Kadia TM; Garcia-Manero G; Bueso-Ramos CE; DiNardo CD; Bledsoe S; Daver NG; Popat U; Konopleva MY; Zhou L; Pierce S; Estrov ZE; Borthakur GM; Ohanian M; Qiao W; Masarova L; Wang X; Mak PY; Cortes J; Jabbour E; Verstovsek S
Blood Adv; 2021 Aug; 5(16):3163-3173. PubMed ID: 34424319
[TBL] [Abstract][Full Text] [Related]
15. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
[TBL] [Abstract][Full Text] [Related]
16. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
[TBL] [Abstract][Full Text] [Related]
17. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Chowdhury O; O'Sullivan J; Barkas N; Wang G; Buck G; Hamblin A; Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; Ribrag V; Schiller G; Vannucchi AM; Zhou D; McMullin MF; Zhong J; Gale RP; Mead AJ;
Leukemia; 2021 Apr; 35(4):1197-1202. PubMed ID: 32770086
[No Abstract] [Full Text] [Related]
18. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.
Platzbecker U; Fenaux P; Adès L; Giagounidis A; Santini V; van de Loosdrecht AA; Bowen D; de Witte T; Garcia-Manero G; Hellström-Lindberg E; Germing U; Stauder R; Malcovati L; Sekeres MA; Steensma DP; Gloaguen S
Blood; 2019 Mar; 133(10):1020-1030. PubMed ID: 30404811
[TBL] [Abstract][Full Text] [Related]
19. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Savona MR; Malcovati L; Komrokji R; Tiu RV; Mughal TI; Orazi A; Kiladjian JJ; Padron E; Solary E; Tibes R; Itzykson R; Cazzola M; Mesa R; Maciejewski J; Fenaux P; Garcia-Manero G; Gerds A; Sanz G; Niemeyer CM; Cervantes F; Germing U; Cross NC; List AF;
Blood; 2015 Mar; 125(12):1857-65. PubMed ID: 25624319
[TBL] [Abstract][Full Text] [Related]
20. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
